pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Centessa Pharmaceuticals plc ($CNTA) · news · pharmadog
← back to Centessa Pharmaceuticals plc
News mentioning $CNTA
14
stories
3d
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
biospace
10d
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
biospace
17d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Aug 31, 26
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
biospace
Aug 31, 26
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
fiercebiotech
Aug 21, 26
‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
fiercebiotech
Aug 19, 26
Takeda leads wave of orexin drugs with potential to upend narcolepsy market
biospace
Aug 6, 26
Takeda approval ushers in new wave of sleep drugs
biopharma dive
Aug 5, 26
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Jul 23, 26
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
Jul 16, 26
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
biopharma dive
Jun 16, 26
Lilly buys non-opioid pain drugmaker 4E
biopharma dive
May 8, 26
Lilly, Gilead lead pharma’s M&A boom
biopharma dive
